Fort Lauderdale, FL, August 11, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQX: OMCM), a global leading provider of clinical data management technology, announced survey results representing leading clinical research and development organizations. The survey respondents included 16 sponsor organizations and 13 contract research organizations (CROs). The results indicate a significant movement forward in the industry towards active risk-based monitoring (RBM) adoption with 76% of the organizations reporting that they are either already executing RBM studies (45%) or planning to initiate RBM studies during this year (31%). The survey further elucidated differences in RBM adoption between CROs and sponsors. 33% of CROs have already initiated RBM studies compared to 53% of sponsors. This result re-enforces the relative hesitance that many have observed from the CRO industry with respect to RBM. The value potential of RBM is often less immediately recognized by CROs vs. sponsors, and many instead perceive a threat to study revenues related to site monitoring. Given the inevitable full adoption of RBM across the industry, CROs who pro-actively embrace this new paradigm will undoubtedly see a competitive advantage in the coming years.
Collectively, the respondents also indicated that the biggest barrier to successful RBM adoption is the perceived complexity and associated burden with implementing an RBM methodology – 63% of all respondents.
“These results reflect what we have assessed to be a key challenge for organizations moving forward. There has been a significant volume of RBM methodology guidance and advice emerging over the past couple of years, following the regulatory papers issued by FDA and EMA,” states Steve Young, senior director of transformation services, OmniComm Systems. “And while much of the advice has been helpful, there has been an unfortunate – and mostly unintended – level of over-engineering in this methodology support. Our OmniComm RBM consulting team understands the source of this over- engineering, and has developed a methodology framework that – together with the RBM-enabling functionality built directly into our advanced TrialMaster® EDC solution - is helping our clients cut through all of the guidance and focus on a simple, thoughtful approach to ensure RBM success.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.